Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a cancer drug stop liver tumors from returning after ablation?

NCT ID NCT06248554

Disease control Sponsor: Chen Xiaoping Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Aug 11, 2026 · Updated 3 times

Summary

This study is testing whether giving a PD-1 inhibitor (a type of immunotherapy) after microwave ablation can help prevent early-stage liver cancer from coming back. About 200 adults with early liver cancer will receive the drug every three weeks for nine cycles. The main goal is to see if it extends the time before the cancer returns or death occurs.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
PD-1 inhibitor (a type of immunotherapy drug)
What this could lead to
If it works, this could offer a way to lower the chance of liver cancer coming back after standard ablation treatment.
What could go wrong
This is an early-phase study without a comparison group, so results are uncertain. Immunotherapy can cause side effects like fatigue, rash, or more serious immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

251 people

The number who actually took part.

Started

Jan 2021

Finished

Jul 2026

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 75 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Aged 18-75 years * Pathological type is HCC, BCLC stage 0-A * No extrahepatic HCC * No radiographic recurrence at 2-4 weeks after ablation * Eastern Cooperative Oncology Group (ECOG) performing status of 0-1 * Child-Pugh grade A or B and adequate hematologic and organ function Exclusion Criteria: * Any history of other malignant tumors or recurrent HCC * Any preoperative treatment for HCC including local and systemic therapy * Any acute active infectious diseases, active or history of autoimmune disease, or immune deficiency * Any persistent serious ablation-related complications * Esophageal and/or gastric variceal bleeding within 6 months * Inability or refusal to comply with the treatment and monitoring * Participation in other clinical trials

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatocellular carcinoma are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatocellular carcinoma

Contacts and locations

Locations

  • Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

    Wuhan, 430000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.